AilsynBio

AilsynBio uses self-developed AI models for De Novo Design (AI generative drug design), combining "Multi-omics data" to design innovative molecules, shortening the drug development cycle. Unlike traditional target screening, De Novo Design generates entirely new molecular structures from scratch.